Ask AI

Capsule Summaries

Share

Program Content

Activities

  • ACTG A5391 DO IT
    ACTG A5391/DO-IT Trial: Switching to DOR ± TDF vs Continuing INSTI + TAF/FTC in People With Obesity and HIV Infection
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 15, 2025

  • Ulonivirine and Islatravir
    Switch to Ulonivirine + Islatravir in Adults With Virologically Suppressed HIV-1: Phase IIb Trial
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 15, 2025

  • Real-world LA CAB + RPV With Viremia in OPERA
    Switch to LA CAB + RPV in People With HIV and Detectable Viral Load in OPERA Cohort
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 16, 2025

  • TECAIN
    TECAIN: Randomized Trial of Topical Trichloroacetic Acid vs Electrocautery for AIN in People With HIV Infection
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 17, 2025

  • SaDAPT
    SaDAPT: Same-Day ART for People With HIV and Presumptive TB in Lesotho and Malawi
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 17, 2025

  • HBV Risk With LA ART
    IMPALA Subanalysis: Risk of de novo HBV Infection in Nonimmune People With HIV Using LA CAB + RPV ART
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 17, 2025

  • VOLITION
    VOLITION: Interim Analysis From Phase IIIb Trial of Optional Switch to LA CAB + RPV Following ART Initiation on DTG/3TC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 17, 2025

  • ODYSSEY Substudy
    ODYSSEY: Predictors of First-line ART Failure in Children With HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 17, 2025

  • Trio
    Predictors of Significant Weight Gain in People With HIV on ART in the Trio Cohort Over 3-Year Period: Retrospective Analysis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 30, 2025

  • BREATHER Plus
    BREATHER Plus: Short-Cycle vs Continuous ART in Adolescents Living With HIV Receiving DTG + TDF/3TC in Sub-Saharan Africa
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 17, 2025

  • IMPALA
    IMPALA: Long-acting Cabotegravir + Rilpivirine in Adults With Poorly Controlled HIV Infection in Sub-Saharan Africa
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 18, 2025

  • HRF-10071 Phase IIa
    HRF-10071: Phase IIa Dose-Ranging, Monotherapy Trial of a Next-generation HIV-1 Maturation Inhibitor in People With HIV Infection
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 18, 2025

  • MK 8527
    Phase IIa Trial of Once-Monthly MK-8527 as Oral PrEP in Adults at Low Risk of HIV-1 Exposure
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 18, 2025

  • Pregnancy Outcomes With CAB
    Antiretroviral Pregnancy Registry Analysis of Pregnancy and Neonatal Outcomes Following Prenatal Cabotegravir Exposure 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 18, 2025

  • PALM 007 Safety
    PALM 007: Safety of Tecovirimat for the Treatment of Mpox in the Democratic Republic of Congo
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 21, 2025

  • PURPOSE 1 Substudy
    PURPOSE 1 Substudy: Efficacy, Safety, and PK of Lenacapavir for PrEP in Pregnant and Lactating People
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 22, 2025

  • PURPOSE 1 and PURPOSE 2 Results in Adolescents and Young Adults
    PURPOSE 1 and PURPOSE 2: Efficacy, Safety, and PK of Twice-Yearly Subcutaneous Lenacapavir for PrEP in Adolescents and Young Adults
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 22, 2025

  • LEN PrEP Patient Preferences
    PURPOSE 2: PrEP Administration Preferences Among Cisgender Men and Gender Diverse Individuals
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 23, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner